Yellow fever vaccines and international travelers

Expert Review of Vaccines

Volumn 7, Issue 5, 2008, Pages 579-587

  Barnett, Elizabeth D ^a   Wilder Smith, Annelies ^b   Wilson, Mary E ^c,d,e  

^a BOSTON MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Traveler; Yellow fever; Yellow fever vaccine; Yellow fever vaccine associated adverse event

Indexed keywords

YELLOW FEVER VACCINE;

CLINICAL FEATURE; DRUG CONTRAINDICATION; DRUG INDICATION; EPIDEMIC; FEVER; HEADACHE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INFECTION RISK; JAUNDICE; MULTIPLE ORGAN FAILURE; MYALGIA; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRAVEL; VIRUS TRANSMISSION; YELLOW FEVER;

ANIMALS; ENDEMIC DISEASES; HUMANS; TRAVEL; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; ZOONOSES;

EID: 45849096080     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.5.579     Document Type: Review

References (52)

1. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin. Infect. Dis. 34(10), 1369-1378 (2002). • Overview of the risk of yellow fever to international travelers.
2. Monath TP. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am. J. Trop. Med. Hyg. 45, 1-43 (1991).
3. Robertson SE, Hull BP, Tomori O et al. Yellow fever: a decade of reemergence. JAMA 276, 1157-1162 (1996).
4. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines. Plotkin S, Orenstein W, Offit P (Eds). Elsevier, UK 959-1055 (2008). •• Very comprehensive review on yellow fever vaccines with more than 600 references.
5. Powell JM. Bring Out Your Dead: the Great Plague of Yellow Fever in Philadelphia in 1793. University of Pennsylvania Press, PA, USA (1949).
6. Bloom KJ. The Mississippi Valley's Great Yellow Fever Epidemic of 1878. Louisiana State University Press, LA, USA (1993).
7. Humphreys M. Yellow Fever and the South. Rutgers University Press, NJ, USA (1992).
8. Carrigan JA. The Saffron Scourge: a History of Yellow Fever in Louisiana 1796-1905. University of Southwestern Louisiana, LA, USA (1994).
9. Sanders EJ, Marfin AA, Tukei PM et al. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am. J. Trop. Med. Hyg. 59, 644-649 (1998).
10. Wilson ME, Chen LH, Barnett ED. Yellow fever immunizations: indications and risks. Curr. Infect. Dis. Rep. 6(1), 34-42 (2004).
11. Barnett ED. Yellow fever: epidemiology and prevention. Clin. Infect. Dis. 44(6), 850-856 (2007).
12. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv. Virus Res. 60, 343-395 (2003).
13. Nasisi A, Monath TP, DeCock K et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans. R. Soc. Trop. Med. Hyg. 83, 401-406 (1989).
14. Rozenzweig EC, Babione RW, Wisseman CL Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am. J. Trop. Med. Hyg. 12, 230-235 (1963).
15. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody to yellow fever virus 30-35 years following immunization with 17D yellow fever vaccine: a study of World War II veterans in 1975-1976. Bull. World Health Organ. 59, 895-900 (1981). • Underlines the long duration of protection of yellow fever vaccination.
16. Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull. World Health Organ. 27, 699-707 (1962).
17. Hepburn MJ, Kortepeter MG, Pittman PR et al. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine 24, 2843-2849 (2006).
18. Sweet BH, Wisseman CJ Jr, Kitaoka M. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subjects following administration of 17D yellow fever vaccine. Am. J. Trop. Med. Hyg. 11, 652 (1962).
19. Pond WL, Ehrenkranz JN, Danauskas JX, Carter MJ. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue. J. Immunol. 98, 673-682 (1967).
20. Belmusto-Worn VE, Sanchez JL, McCarthy K et al. Randomized, double-blind, Phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am. J. Trop. Med. Hyg. 72, 187-197 (2005).
21. Hacker UT, Jelinek T, Erhardt S et al. In vivo synthesis of tumor necrosis factor-? in healthy humans after live yellow fever vaccination. J. Infect. Dis. 177, 774-778 (1998).
22. Reinhardt B, Jaspert R, Niedrig M et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56, 159-167 (1998).
23. Martins MA, Silva ML, Marciano AP et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol. 148, 90-100 (2007).
24. Martins MA, Silva ML, Eloi-Santos SM et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26, 1173-1184 (2008).
25. Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine 25, 2941-2950 (2007).
26. Vellozzi C, Mitchell T, Miller E et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am. J. Trop. Med. Hyg. 75, 333-336 (2006).
27. Centers for Disease Control and Prevention. Yellow fever vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 51(RR-17), 4-6 (2002)
28. McMahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25, 1727-1734 (2007).
29. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. 85, 131-134 (2002).
30. Eidex RB, Hayes EB, Russell M. Yellow fever. In: Centers for Disease Control and Prevention. Health Information for International Travel (2008). US Department of Health and Human Services, Public Health Service, GA, USA (2007).
31. Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23, 3256-3263 (2005). •• Pivotal paper in understanding the risk factors associated with the current live yellow fever vaccine.
32. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb. Mortal. Wkly Rep. 51, 989-993 (2002).
33. Fernandes GC, Camacho LAB, Carvalho MS, Batista M, de Almeida SMR. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 25, 3124-3128 (2007).
34. Bae H-G, Domingo C, Tenorio A et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J. Infect. Dis. 197, 1577-1584 (2008).
35. Centers for Disease Control and Prevention. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR Morb. Mortal. Wkly Rep. 50, 643-645 (2001).
36. Engel AR, Vasconcelos PFC, McArthur MA, Barrett ADT. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24, 2803-2809 (2006).
37. Martin M, Weld LH, Tsai TF et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis. 7, 945-951 (2001).
38. Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Human Vaccines 1(5), e1-e8 (2005).
39. Barwick RE. History of thymoma and yellow fever vaccination. Lancet 364, 936 (2004).
40. Tsai T. Congenital arboviral infections: something new, something old. Pediatrics 117, 936-939 (2006).
41. Nishioka Sde A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop. Med. Int. Health 3(1), 29-33 (1998).
42. Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24(9), 1421-1426 (2006).
43. Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87(3), 337-339 (1993).
44. Wilder-Smith A, Hill D, Freedman DO. Practical implications of the revised international vaccine certificate. Am. J. Trop. Med. Hyg. 78(3), 359-360 (2008). • Provides an overview on the practical implications of recent changes to the International Certificate of Vaccination or Prophylaxis.
45. Hardiman M, Wilder-Smith A. The revised international health regulations and their relevance to travel medicine. J. Travel Med. 14(3), 141-144 (2007).
46. Guirakhoo F, Arroyo J, Pugachev KV et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75(16), 7290-7304 (2001).
47. Centers for Disease Control and Prevention. Yellow fever in Paraguay - updated wwwn.cdc.gov/travel/contentYellowFever Paraguay.aspx (Accessed June 2008)
48. Centers for Disease Control and Prevention. Yellow fever alert for Brazil wwwn.cdc.gov/travel/contentYellowFeverBrazil.aspx (Accessed June 2008)
49. Centers for Disease Control and Prevention. Yellow fever in Argentina - updated wwwn.cdc.gov/travel/contentYellowFever Argentina.aspx (Accessed June 2008)
50. Centers for Disease Control and Prevention. Yellow fever vaccine: what you need to know www.cdc.gov/vaccines/pubs/vis/downloads/vis-yf.pdf (Accessed June 2008)
51. MedlinePlus www.nlm.nih.gov/medlineplus/news/fullstory_61608.html
52. Centers for Disease Control and Prevention www.cdc.gov